Our mission is to heal the brain.

We are committed to redefine brain health with game changer cerebral healers.

We target the neuronal microtubules, a key structure of neuronal healthy function, plasticity and resilience. Our MoA unlocks numerous therapeutic areas across CNS indications.

Our primary objective is to treat severe psychiatric conditions.

Our lead asset is a first-in-class small molecule of high therapeutic index, index and disease modifying potential, with phase 2a data in MDD/TRD.

MAPREG has established early pipeline opportunities addressing unmet challenges in brain health.

Our key shareholders are a global health insurer company, FO & high net-worth individuals.

We invite biopharmas & investors to join MAPREG’s journey to Heal the Brain.